Evidence map›Paper›PMID 31607427›Full record

ArticleAmerican journal of human genetics2019

Finding Diagnostically Useful Patterns in Quantitative Phenotypic Data.

Stuart Aitken, Helen V Firth, Jeremy McRae, Mihail Halachev, Usha Kini, Michael J Parker, Melissa M Lees, Katherine Lachlan, Ajoy Sarkar, Shelagh Joss and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

Stuart AitkenMRC Human Genetics Unit, Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
Helen V FirthWellcome Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK; Clinical Genetic Department, Addenbrooke's Hospital Cambridge University Hospitals, Cambridge, UK.
Jeremy McRaeWellcome Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK.
Mihail HalachevMRC Human Genetics Unit, Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK; South East Scotland Regional Genetics Services, Western General Hospital, Edinburgh, UK.
Usha KiniOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Michael J ParkerSheffield Children's Hospital NHS Foundation Trust, Western Bank, Sheffield, UK.
Melissa M LeesNorth East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3EH, UK.
Katherine LachlanWessex Clinical Genetics Service, University Hospitals of Southampton NHS Trust, Southampton, UK.
Ajoy SarkarNottingham Regional Genetics Service, City Hospital Campus, Nottingham University Hospitals NHS Trust, The Gables, Hucknall Road, Nottingham NG5 1PB, UK.
Shelagh JossWest of Scotland Regional Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.
Miranda SplittNorthern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Shane McKeeNorthern Ireland Regional Genetics Service, Belfast City Hospital, Belfast BT9 7AB, UK.
Andrea H NémethOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford Centre for Genomic Medicine, Oxford University Hospitals National Health Service Foundation Trust, Oxford, UK.
Richard H ScottNorth East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3EH, UK.
Caroline F WrightUniversity of Exeter Medical School, RILD Level 4, Royal Devon & Exeter Hospital, Barrack Road, Exeter, UK.
Joseph A MarshMRC Human Genetics Unit, Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
Matthew E HurlesWellcome Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK.
David R FitzPatrickMRC Human Genetics Unit, Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK. Electronic address: david.fitzpatrick@ed.ac.uk.
DDD StudyWellcome Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK.
Institute of Genetics and Cancer · GBWellcome Sanger Institute · GBUniversity of Exeter · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBQueen Elizabeth University Hospital · GBSheffield Children's NHS Foundation Trust · GBNottingham University Hospitals NHS Trust · GBOxford University Hospitals NHS Trust · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GBUniversity of Ulster · GBNational Health Service · GBWestern General Hospital · GB

Funding

Medical Research Council MC_PC_16018Medical Research Council MC_UP_1502/3Medical Research Council MC_UU_00007/3Medical Research Council MR/M02122X/1Wellcome Trust
6 · The paper itself

Abstract

Trio-based whole-exome sequence (WES) data have established confident genetic diagnoses in ∼40% of previously undiagnosed individuals recruited to the Deciphering Developmental Disorders (DDD) study. Here we aim to use the breadth of phenotypic information recorded in DDD to augment diagnosis and disease variant discovery in probands. Median Euclidean distances (mEuD) were employed as a simple measure of similarity of quantitative phenotypic data within sets of ≥10 individuals with plausibly causative de novo mutations (DNM) in 28 different developmental disorder genes. 13/28 (46.4%) showed significant similarity for growth or developmental milestone metrics, 10/28 (35.7%) showed similarity in HPO term usage, and 12/28 (43%) showed no phenotypic similarity. Pairwise comparisons of individuals with high-impact inherited variants to the 32 individuals with causative DNM in ANKRD11 using only growth z-scores highlighted 5 likely causative inherited variants and two unrecognized DNM resulting in an 18% diagnostic uplift for this gene. Using an independent approach, naive Bayes classification of growth and developmental data produced reasonably discriminative models for the 24 DNM genes with sufficiently complete data. An unsupervised naive Bayes classification of 6,993 probands with WES data and sufficient phenotypic information defined 23 in silico syndromes (ISSs) and was used to test a "phenotype first" approach to the discovery of causative genotypes using WES variants strictly filtered on allele frequency, mutation consequence, and evidence of constraint in humans. This highlighted heterozygous de novo nonsynonymous variants in SPTBN2 as causative in three DDD probands.

Indexed as

Bayes TheoremChildDevelopmental DisabilitiesDwarfismExomeExome SequencingFemaleGene FrequencyGenetic Predisposition to DiseaseHeterozygoteHumansMaleMutationPhenotypeRepressor ProteinsSpectrinRepressor ProteinsSpectrindevelopmental diseasegenotypenaive BayesphenotypetSNE

Identifiers

PMID31607427
PMCPMC6848993
OpenAlexW2979358319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.